If you’ve ever tried navigating the pharmaceutical rebate maze blindfolded, you know it’s not just inefficient, it’s expensive. And not just for pharma companies. Patients feel it. Providers feel it. Hell, even the spreadsheets feel it. Enter RIS Rx, the Newport Beach disruptors turning gross-to-net revenue leakage from an industry headache into an opportunity for transformation.
Founded in 2020 by two PharmDs who got tired of watching affordability programs hemorrhage value, RIS Rx isn’t another “healthtech startup.” It’s a quiet killer in a $90B battleground, armed with software precision and pharmacist-built insight. Gerard Rivera, PharmD, the company’s CEO, and Stephen Hom, PharmD, EVP and Chief Commercial Officer, didn’t just notice inefficiencies, they lived them. So they built a company that could do something about it.
Let’s talk product. Their PreVail® platform doesn’t just sound sharp, it slices through the noise with three clinical-grade scalpel tools: BPS for co-pay diversion, Triple A for pharmacy fraud, and PG360 for charity program misuse. These aren’t feel-good features, they’re revenue-rescue missions. Backed by real-time analytics and guided by real-world pharmacy chops, RIS Rx doesn’t just detect problems, it fixes them before they leak out the back door.
And the industry’s catching on. 160+ drug brands across 23 manufacturers? That’s not traction, it’s a takeover. When your net promoter score is brushing up against perfect, and your clients are among the world’s top life sciences companies, you’re not just solving problems, you’re redefining standards.
Now, with a fresh growth investment from Summit Partners (cue the applause), RIS Rx is stepping on the gas. They’re scaling the team, deepening the platform, and going even harder on client services. Financial giants like Morgan Stanley and Jamieson Corporate Finance advised. Legal powerhouses like Latham & Watkins, DLA Piper, and Kirkland & Ellis got in the ring. This wasn’t a casual round, it was a signal flare. Big players see the upside.
Behind it all is the idea that resilience, innovation, and service, yep, RIS, aren’t just corporate jargon. They’re battle-tested principles. And as the market grapples with the brutal inefficiencies of gross-to-net, RIS Rx isn’t reacting. It’s leading.
This isn’t the future of patient affordability tech. This is the correction. And it’s right on time.
